EXEL
EXEL
NASDAQ · Biotechnology

Exelixis Inc

$54.07
+1.87 (+3.58%)
As of Aug 8, 1:14 AM ET ·
Analyst Consensus
Hold
25
Analysts
High
Coverage
Buy 13 52%
Hold 11 44%
Sell 1 4%
Price Target
Analyst Price Target +114.7% upside
Low Target $78.53
Average Target $116.10
High Target $123.77
Current Price $54.07
Current
$54.07
Target
$116.10
$78.53 $116.10 avg $123.77
Scenario Analysis
Bear Case
$78.53
45.2%
Low target
Base Case
$116.10
+114.7%
Avg target
Bull Case
$123.77
+128.9%
High target
Risk/Reward
2.8x
Favorable
Price in Context
52-Week High
$57.57
-6.1% from high
52-Week Low
$33.76
+60.2% from low
50-Day SMA
$43.59
+24.0% vs SMA
200-Day SMA
$41.49
+30.3% vs SMA
RSI (14)
62.0
Neutral
Target vs 52W High
$116.10
+101.7% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 79% $257.58 +4.7%
AMGN
Amgen Inc
Hold 43 49% $190.87 -53.6%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +172.3%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 40 83% $438.34 -11.6%
REGN
Regeneron Pharmaceuticals
Buy 38 71% $76.80 -90.2%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -55.6%
RVMD
Revolution Medicines Inc
Strong Buy 29 93% $114.11 -44.4%
BIIB
Biogen Inc
Buy 44 64% $91.45 -56.0%